Lymphoma Knowledge Hub

DLBCL Survival Rate Varies Based on Patient Race

A study published in Clinical Lymphoma, Myeloma & Leukemia found that Black patients with diffuse large B-cell lymphoma (DLBCL) have poorer survival outcomes. Multiple studies...
Arthritis Medication May Help Treat Depressive Symptoms

Hodgkin Lymphoma Survivors Face Higher Non-Cancer-Related Mortality Compared with General Population

Survivors of classical Hodgkin lymphoma (cHL) face higher risks of potentially preventable non-lymphoma causes of death compared with the general U.S. population, according to...

HDAC Plus mTOR Treatment Combination Improves Outcomes in Relapsed/Refractory Lymphoma

A phase I study published in Clinical Cancer Research showed that patients with relapsed/refractory Hodgkin lymphoma (HL) who were treated with the histone deacetylase...

Patients with DLBCL May Be Able to Receive Chemotherapy During Pregnancy

A study published in the British Journal of Haematology found that pregnant women with diffuse large B‐cell lymphoma (DLBCL) can receive chemotherapy when treated...

CAR T-Cell Therapy Induces Response in Nearly 75% of Patients with B-Cell Lymphoma

The autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel induced responses in nearly 75% of patients with relapsed/refractory large B-cell lymphoma (LBCL)...

Obinutuzumab Plus Chemotherapy Induces MRD Negativity in Patients with MCL

A study published in The Lancet Haematology found that obinutuzumab plus chemotherapy was well tolerated and induced minimal residual disease (MRD) negativity in the...

Fracture Risk Increased in Patients with DLBCL Receiving First-Line R-CHOP

Among older patients receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as first-line therapy for diffuse large B-cell lymphoma (DLBCL), there is a clinically...

Journal Reading List

Advertisement
Advertisement
click me